Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Sep 26, 2014; 4(3): 144-150
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.144
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.144
Closer look at white-coat hypertension
Nurver Turfaner Sipahioglu, Fikret Sipahioglu, Department of Family Medicine, Cerrahpasa Medical Faculty, Istanbul University, 34303 Istanbul, Turkey
Author contributions: Sipahioglu NT contributed to deciding the subject, writing the manuscript and revising the paper; Sipahioglu F contributed to language editing, finding references, polishing the format.
Correspondence to: Nurver Turfaner Sipahioglu, MD, PhD, Associate Professor, Department of Family Medicine, Cerrahpasa Medical Faculty, Istanbul University, Kaptanı Derya İbrahim Paşa Sokak, 34303 Istanbul, Turkey. nurverdi@gmail.com
Telephone: +90-532-4961773 Fax: +90-212-4143251
Received: November 27, 2013
Revised: July 23, 2014
Accepted: July 27, 2014
Published online: September 26, 2014
Revised: July 23, 2014
Accepted: July 27, 2014
Published online: September 26, 2014
Core Tip
Core tip: There is contradictory information regarding the clinical presentations and prognosis of white-coat hypertension (WCHT). This review aims to summarize recent research and compare it to existing knowledge about WCHT. Published studies on the prevalence of WCHT, the associated target organ damage and cardiovascular markers, and WCHT patient prognosis were reviewed. WCHT may be a marker of future obesity and metabolic syndrome, is related to glucose dysregulation and left ventricular hypertrophy and may progress to sustained hypertension. Clinicians should be aware of the risk factors associated with WCHT, and patients should be closely monitored, especially to identify target organ damage and metabolic syndrome.